Park Ji Young, Kang Hyun Mi, Kwak Eun Min, Rhim Jung-Woo, Ahn Yo Han, Lee Hyunju, Jeong Dae Chul, Kang Jin Han
Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam-si 13620, Gyeonggi-do, Korea.
Department of Pediatrics, Chung-Ang University Hospital, Seoul 06973, Korea.
Antibiotics (Basel). 2020 Dec 16;9(12):915. doi: 10.3390/antibiotics9120915.
Monitoring regional antibiotic resistance patterns of uropathogens are important for deciding suitable empirical antibiotics for urinary tract infections (UTIs) in children. This study aimed to investigate regional differences in antimicrobial susceptibility patterns of and spp. in children below 24 months old, diagnosed with their first episode of UTI, and to find factors associated with an increased risk for UTI caused by extended-spectrum β-lactamase (ESBL)-producing uropathogens. This was a retrospective cohort study of children diagnosed between 2011 and 2017 in four different hospitals located in four different regions of South Korea; regions A, B, C, and D. The government's big data repository was used to acquire data on regional antibiotic prescriptions. The pooled antimicrobial susceptibilities of and spp. ( = 2044) were as follows: ampicillin-sulbactam (61.0%), 3rd generation cephalosporin (3C) (82.8%), and trimethoprim-sulfamethoxazole (72.0%). Multivariate analysis showed that children diagnosed at hospital A (OR, 1.8; 95% confidence interval [CI], 1.2-2.6; = 0.002) and every year that increased in the study period (OR, 1.1; 95% CI, 1.1-1.2; < 0.001) were factors associated with an increased risk for UTIs with ESBL-producers. Regions A and B had significantly higher amounts of oral 3Cs prescribed compared to regions C and D ( = 0.009), which correlate with hospitals in the regions that had higher proportions of UTIs with ESBL-producing uropathogens (A and B vs. C and D, < 0.001). Therefore, children in certain regions are at a higher risk for UTIs caused by ESBL-producers compared to other regions, which correlate with regions that had higher amounts of oral 3Cs prescribed.
监测尿路病原体的区域抗生素耐药模式对于确定适合儿童尿路感染(UTI)的经验性抗生素非常重要。本研究旨在调查24个月以下首次诊断为UTI的儿童中大肠埃希菌和肺炎克雷伯菌属的抗菌药敏模式的区域差异,并找出与产超广谱β-内酰胺酶(ESBL)尿路病原体导致UTI风险增加相关的因素。这是一项对2011年至2017年在韩国四个不同地区的四家不同医院诊断的儿童进行的回顾性队列研究;A、B、C和D地区。利用政府的大数据存储库获取区域抗生素处方数据。大肠埃希菌和肺炎克雷伯菌属(n = 2044)的合并抗菌药敏情况如下:氨苄西林-舒巴坦(61.0%)、第三代头孢菌素(3C)(82.8%)和甲氧苄啶-磺胺甲恶唑(72.0%)。多因素分析显示,在A医院诊断的儿童(比值比[OR],1.8;95%置信区间[CI],1.2 - 2.6;P = 0.002)以及研究期间每增加一年(OR,1.1;95%CI,1.1 - 1.2;P < 0.001)是与产ESBL病原体导致UTI风险增加相关的因素。与C和D地区相比,A和B地区口服3C的处方量显著更高(P = 0.009),这与这些地区产ESBL尿路病原体导致UTI比例较高的医院相关(A和B地区与C和D地区相比,P < 0.001)。因此,与其他地区相比,某些地区的儿童产ESBL病原体导致UTI的风险更高,这与口服3C处方量较高的地区相关。